Skip to main content

Indian Pharma Network

CLOLAR (Clofarabine)

  • Medicine Name: CLOLAR
  • Active Ingredient (API): Clofarabine
  • Dosage Form & Strength: Concentrate for infusion: 20 mg clofarabine in 20 mL (1 mg/mL), single-dose vial
  • Manufactured By: Genzyme Corporation (Sanofi), USA; sold in the EU as Evoltra by Sanofi B.V.

Medical Uses

CLOLAR (clofarabine) is an intravenous chemotherapy medicine for children and young people with acute lymphoblastic leukaemia (ALL) that has relapsed or stopped responding after at least two earlier treatment regimens. The US label covers patients aged 1 to 21 years. In the European Union the same medicine is sold as Evoltra and is used when no other treatment is expected to give a lasting response.

Clofarabine is a nucleoside analogue. Once inside the cell it is converted to an active triphosphate that blocks ribonucleotide reductase, gets built into new DNA strands and halts DNA polymerase, so the leukaemic cell cannot copy or repair its DNA. It also damages the mitochondrial membrane, releasing signals that make the cell die.

Approval rested on a single-arm study of 61 heavily pre-treated children. Seven (11.5%) reached complete remission and five more (8.2%) reached remission without full platelet recovery; the median length of these remissions was about 10.7 weeks. For many patients the aim of treatment is to reach a remission deep enough to go on to a stem cell transplant, and four of the responders did so.

Other options for relapsed ALL include Blincyto (blinatumomab) and Besponsa (inotuzumab ozogamicin); our article on acute lymphoblastic leukaemia treatment explains how they compare.

Warnings & Precautions

  • Bone marrow and infection: blood counts fall sharply after each cycle. In the label’s safety data febrile neutropenia occurred in 55% of patients and 83% had at least one infection, some fatal. Bleeding into the brain, gut or lungs has been reported, mostly when platelets were very low.
  • Capillary leak and SIRS: a rapid inflammatory reaction with low blood pressure, breathlessness and fluid shifts can occur during the 5 infusion days. The drug is stopped at once if it appears; the label says preventive hydrocortisone on days 1 to 3 may help.
  • Tumour lysis: as leukaemic cells break down, uric acid and potassium can rise. Children receive IV fluids and uric-acid-lowering treatment throughout the cycle.
  • Liver and kidneys: severe and sometimes fatal liver injury, including veno-occlusive disease, has been reported, and the risk is higher after a previous stem cell transplant. Kidney function is checked often; the dose is halved when creatinine clearance is 30–60 mL/min. The European label does not allow use with severe liver or kidney impairment.
  • Serious bowel inflammation (enterocolitis, including C. difficile colitis) and severe skin reactions such as Stevens-Johnson syndrome have occurred; both need urgent attention.
  • It can harm an unborn baby. Girls and women who could become pregnant should use contraception during treatment and for 6 months after the last dose, and males with a female partner for 3 months. Breastfeeding is not allowed during treatment.
  • Very common side effects in the label’s studies were vomiting (78%), nausea (73%), diarrhoea (56%), itching (43%), headache (43%), fever (39%), rash (38%) and fast heartbeat (35%).

Documentation & Availability

How many vials are used per cycle?

The dose is 52 mg per square metre of body surface, infused over 2 hours once a day for 5 days. A child of 1 m² needs about 52 mg a day, which is three 20 mg vials a day and roughly 13 to 15 vials per cycle, depending on how the hospital pharmacy pools doses. Cycles are repeated every 2 to 6 weeks once blood counts recover; most patients in the study had 2 cycles.

Which documents are needed?
  • Haematologist’s prescription with body surface area, daily dose and number of cycles
  • Bone marrow or flow cytometry report confirming relapsed or refractory ALL, with a summary of earlier regimens
  • Recent liver and kidney function tests
  • Patient ID and the name of the treating hospital

Imported vials are supplied only for the named patient against these papers.

How is the vial stored?

At room temperature (up to 25 °C) in its carton; it must not be frozen. The hospital pharmacy filters and dilutes it in saline or dextrose and uses it within 24 hours.

Is clofarabine available in India?

Yes. CDSCO approved clofarabine 20 mg/20 mL injection in 2018 for the same childhood ALL use, and Indian brands such as Cfara (Zydus) and Farabine (Intas) are listed on Indian pharmacy sites, though stock can be patchy. Most families will use an Indian brand. We help when the doctor specifically wants the original Sanofi product (Evoltra) or when Indian stock cannot be found in time.

Sourcing & Delivery

The US CLOLAR brand is now listed by the FDA as discontinued, and US hospitals use generic clofarabine instead. The original Sanofi medicine is still authorised in Europe as Evoltra, so an import request for the brand is usually met with the European pack. Tell us whether the doctor needs the original brand or will accept an approved generic, and we will confirm what can be supplied and how fast.

For CLOLAR / Evoltra (clofarabine) price in India or availability, call +91 96548 60915 or +91 93100 90915, WhatsApp +91 98104 69557, use our toll-free number 1800 1200 365, or email info@indianpharmanetwork.in.

Global Approval Status:

  • United States: first approved in 2004 (NDA 021673, Genzyme); the brand is listed as discontinued, while several generic clofarabine injections are approved and marketed.
  • European Union: Evoltra authorised on 29 May 2006 under exceptional circumstances; Sanofi B.V. holds the licence.
  • India: clofarabine 20 mg/20 mL injection approved by CDSCO in January 2018; Indian brands are marketed.

Sources:

Information last checked: November 2026.

FAQ

What is CLOLAR used for?

Acute lymphoblastic leukaemia in children and young adults (1 to 21 years in the US) that has come back or not responded after at least two earlier treatments.

Are CLOLAR and Evoltra the same medicine?

Yes. Both are Sanofi’s clofarabine 1 mg/mL infusion; CLOLAR was the US name and Evoltra is the European name.

How is clofarabine given?

As a 2-hour drip into a vein once a day for 5 days, in hospital, with fluids and close monitoring.

Can adults receive it?

The labels are for children and young people; the European label says there is not enough data in adults.

Is there an Indian version?

Yes, Indian clofarabine injections are approved and sold; the imported brand is mainly for cases where a doctor asks for it specifically.

Contact Patient Support

If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.

Product Enquiry